X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (902) 902
Publication (66) 66
Newspaper Article (19) 19
Book Chapter (10) 10
Newsletter (5) 5
Book Review (4) 4
Book / eBook (3) 3
Conference Proceeding (3) 3
Dissertation (3) 3
Trade Publication Article (2) 2
Paper (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (483) 483
humans (446) 446
boron compounds - pharmacokinetics (358) 358
index medicus (322) 322
boron neutron capture therapy (274) 274
boron (259) 259
male (230) 230
mice (228) 228
oncology (183) 183
tissue distribution (183) 183
rats (181) 181
female (180) 180
boron neutron capture therapy - methods (168) 168
cancer (159) 159
phenylalanine - analogs & derivatives (152) 152
radiology, nuclear medicine & medical imaging (151) 151
boron compounds - therapeutic use (148) 148
neutron-capture therapy (147) 147
bnct (144) 144
boron compounds - chemistry (141) 141
phenylalanine - pharmacokinetics (129) 129
pharmacology & pharmacy (125) 125
boron compounds - administration & dosage (123) 123
tumors (121) 121
brain neoplasms - radiotherapy (119) 119
boron - pharmacokinetics (105) 105
cell line, tumor (101) 101
pharmacokinetics (99) 99
boron compounds - pharmacology (87) 87
boronophenylalanine (86) 86
sulfhydryl compounds - pharmacokinetics (81) 81
biodistribution (79) 79
biochemistry & molecular biology (78) 78
chemistry, multidisciplinary (76) 76
middle aged (75) 75
chemistry (74) 74
borohydrides - pharmacokinetics (73) 73
medicine & public health (73) 73
brain neoplasms - metabolism (72) 72
chemistry, medicinal (68) 68
cells (65) 65
glioma - metabolism (65) 65
tumor cells, cultured (65) 65
aged (63) 63
neutrons (62) 62
phenylalanine - therapeutic use (62) 62
adult (61) 61
glioma - radiotherapy (59) 59
analysis (57) 57
glioma (57) 57
therapy (56) 56
boron compounds (55) 55
mice, inbred balb c (55) 55
neutron capture therapy (55) 55
radiation-sensitizing agents - pharmacokinetics (55) 55
mice, nude (54) 54
chemistry, inorganic & nuclear (53) 53
melanoma (53) 53
rats, inbred f344 (53) 53
isotopes (52) 52
nuclear science & technology (52) 52
care and treatment (51) 51
in-vitro (51) 51
molecular structure (51) 51
dose-response relationship, drug (49) 49
radiotherapy (49) 49
toxicity (49) 49
article (47) 47
boron compounds - chemical synthesis (47) 47
brain-tumors (47) 47
boron-neutron capture therapy (46) 46
drugs (46) 46
research (46) 46
clinical neurology (45) 45
derivatives (45) 45
glioblastoma-multiforme (45) 45
glycine - analogs & derivatives (45) 45
chemistry, organic (44) 44
neoplasm transplantation (44) 44
radiotherapy dosage (44) 44
delivery (42) 42
drug delivery systems (41) 41
biology (40) 40
glioblastoma - radiotherapy (40) 40
boron - therapeutic use (39) 39
brain (39) 39
bsh (39) 39
p-boronophenylalanine (39) 39
phenylalanine - administration & dosage (39) 39
time factors (39) 39
tumor (39) 39
blood (38) 38
bor (38) 38
glioblastoma (38) 38
neoplasms - radiotherapy (38) 38
proteins (38) 38
cricetinae (37) 37
fluorescence (37) 37
nanoparticles (37) 37
radiation-sensitizing agents - therapeutic use (37) 37
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of Clinical Pharmacology, ISSN 0091-2700, 02/2018, Volume 58, Issue 2, pp. 180 - 192
Journal Article
Investigational New Drugs, ISSN 0167-6997, 6/2018, Volume 36, Issue 3, pp. 407 - 415
This two-part, phase I study evaluated the mass balance, excretion, pharmacokinetics (PK), and safety of ixazomib in patients with advanced solid tumors. In... 
Mass balance | Medicine & Public Health | ADME | AMS | Total radioactivity | Oncology | Pharmacology/Toxicology | Pharmacokinetics | Ixazomib | DEXAMETHASONE | SAFETY | BORTEZOMIB | RENAL IMPAIRMENT | RELAPSED/REFRACTORY MULTIPLE-MYELOMA | ONCOLOGY | DRUGS | Pharmacolcinetics | LENALIDOMIDE | PHARMACOLOGY & PHARMACY | SPECTROMETRY | BLOOD | Carbon Radioisotopes - blood | Glycine - analogs & derivatives | Glycine - therapeutic use | Humans | Middle Aged | Male | Boron Compounds - administration & dosage | Female | Feces | Carbon Radioisotopes - administration & dosage | Proteasome Inhibitors - blood | Glycine - administration & dosage | Proteasome Inhibitors - pharmacokinetics | Radioactivity | Glycine - pharmacokinetics | Urine | Glycine - blood | Administration, Oral | Carbon Radioisotopes - pharmacokinetics | Proteasome Inhibitors - administration & dosage | Boron Compounds - pharmacokinetics | Treatment Outcome | Proteasome Inhibitors - therapeutic use | Neoplasms - drug therapy | Aged | Neoplasm Staging | Neoplasms - pathology | Boron Compounds - blood | Boron Compounds - therapeutic use | Excretion | Oral administration | Mass spectroscopy | Pharmacology | Patients | Proteasome inhibitors | Studies | Metabolites | Gastrointestinal system | Solid tumors | Mass spectrometry | Carbon 14 | Drug dosages | Tumors | Phase I Studies
Journal Article
British Journal of Haematology, ISSN 0007-1048, 09/2016, Volume 174, Issue 5, pp. 748 - 759
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 09/2016, Volume 82, Issue 3, pp. 728 - 738
Journal Article
Journal Article
Blood, ISSN 0006-4971, 08/2014, Volume 124, Issue 7, pp. 1047 - 1055
Journal Article
Journal Article
Drugs, ISSN 0012-6667, 03/2016, Volume 76, Issue 3, pp. 405 - 411
Journal Article
British Journal of Haematology, ISSN 0007-1048, 07/2018, Volume 182, Issue 2, pp. 231 - 244
Summary Weekly ixazomib with lenalidomide‐dexamethasone (Rd) is feasible and has shown activity in newly diagnosed multiple myeloma (NDMM) patients. This phase... 
newly diagnosed | multiple myeloma | oral | ixazomib | twice‐weekly | twice-weekly | BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE | PROTEASOME INHIBITOR IXAZOMIB | CYCLOPHOSPHAMIDE | AUTOLOGOUS TRANSPLANTATION | OPEN-LABEL | MAINTENANCE THERAPY | CARFILZOMIB | CONSOLIDATION THERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | LOW-DOSE DEXAMETHASONE | Glycine - analogs & derivatives | Glycine - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Boron Compounds - administration & dosage | Dose-Response Relationship, Drug | Multiple Myeloma - drug therapy | Aged, 80 and over | Lenalidomide - pharmacokinetics | Adult | Female | Glycine - administration & dosage | Glycine - pharmacokinetics | Dexamethasone - administration & dosage | Drug Administration Schedule | Administration, Oral | Boron Compounds - pharmacokinetics | Treatment Outcome | Dexamethasone - pharmacokinetics | Disease-Free Survival | Lenalidomide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lenalidomide - adverse effects | Boron Compounds - adverse effects | Aged | Complications and side effects | Medical research | Care and treatment | Hyperglycemia | Dexamethasone | Multiple myeloma | Medicine, Experimental | Steroids | Toxicity | Pharmacology | Pharmacokinetics | Peripheral neuropathy | Patients | Drug dosages | Index Medicus | Haematological Malignancy | Research Paper
Journal Article
Journal Article